Issue Date: June 17, 2013 | Web Date: June 14, 2013
AstraZeneca Buys Pearl Therapeutics
In a bid to stay competitive in treating respiratory diseases, AstraZeneca is paying up to $1.15 billion for the privately held biotech firm Pearl Therapeutics. The acquisition is the latest in the British drugcompany’s piecemeal rebuilding of a new-product pipeline that has fallen apart inrecent years.
AstraZeneca brought in Pascal Soriot as CEO last October to find new products that could offset patent losses on top-selling drugs such as the . . .
To view the rest of this content, please log in with your ACS ID.
- Chemical & Engineering News
- ISSN 0009-2347
- Copyright © American Chemical Society